ACGME Program Requirements for Graduate Medical Education in Hematology

Summary and Impact of Major Requirement Revisions (For second review and comment period April 3, 2023)

Below are proposed changes to the Program Requirements for Graduate Medical Education in Hematology.

Requirement #: II.B.3.c).(1)

Requirement Revision (significant change only):

Faculty members who are ABIM- or AOBIM-certified in <u>cardiovascular disease</u>, endocrinology, gastroenterology, <u>hospice and palliative medicine</u>, infectious disease, medical oncology, and pulmonary disease should be available to participate in the education of fellows. (Core)

- Describe the Review Committee's rationale for this revision:
 This requirement was updated based on feedback from the hematology community to include those faculty members who are essential participants in the education of fellows.
- How will the proposed requirement or revision improve resident/fellow education, patient safety, and/or patient care quality?
 The faculty members in these subspecialties will ensure that fellows have adequate education in the multidisciplinary, quality care of hematology and medical oncology patients.
- 3. How will the proposed requirement or revision impact continuity of patient care? **N/A**
- 4. Will the proposed requirement or revision necessitate additional institutional resources (e.g., facilities, organization of other services, addition of faculty members, financial support; volume and variety of patients), if so, how? The addition of these faculty members may necessitate additional resources for Sponsoring Institutions/programs which do not presently include these members

in the education of fellows. The impact of this change is not known at this time.

5. How will the proposed revision impact other accredited programs?
N/A

Requirement #: "New" IV.B.1.b).(1).(d).(ii) - (iv), IV.B.1.b).(1).(d).(vi).(a) - (b), IV.B.1.b).(2).(b).(ii), IV.B.1.b).(2).(b).(v), IV.B.1.c).(12)

Requirement Revision (significant change only):

[Fellows must demonstrate competence in the:]

IV.B.1.b).(1).(d).(ii) hematologic care of pregnant patients and women of

reproductive age; (Core)

IV.B.1.b).(1).(d).(iii) hematologic care of transgendered patients; (Core)

IV.B.1.b).(1).(d).(iv) <u>hematologic complications of infectious diseases; (Core)</u>

and management of neeplastic malignant disorders of the: IV.B.1.b).(1).(d).(vi).(a) Iymphoid organs, including lymphomas, myeloma, and plasma cell dyscrasias; and, (Core) IV.B.1.b).(1).(d).(vi).(b) hematopoietic system, including myeloproliferative neoplasms, myelodysplasias, acute and chronic leukemias, Castleman disease, and dendritic cell disorders; (Core) IV.B.1.b).(2).(b).(ii) assessment of hematologic disorder severity and/or stage, as measured by physical signs and laboratory evaluation; (Core) IV.B.1.b).(2).(b).(v) indications for and application of immunophenotypic and molecular studies for patients with neoplastic and blood disorders; (Core) IV.B.1.c).(12) Fellows must demonstrate knowledge of the indications, complications, and risks and limitations associated with lesion biopsy detection of circulating DNA for disease specific markers. (Core)		
IV.B.1.b).(1).(d).(vi).(b) hematopoietic system, including myeloproliferative neoplasms, myelodysplasias, acute and chronic leukemias, Castleman disease, and dendritic cell disorders; (Core) IV.B.1.b).(2).(b).(ii) assessment of hematologic disorder severity and/or stage, as measured by physical signs and laboratory evaluation; (Core) IV.B.1.b).(2).(b).(v) indications for and application of immunophenotypic and molecular studies for patients with neoplastic and blood disorders; (Core) IV.B.1.c).(12) Fellows must demonstrate knowledge of the indications, complications, and risks and limitations associated with lesion biopsy detection of circulating DNA for disease specific markers. (Core)	IV.B.1.b).(1).(d).(vi)	
IV.B.1.b).(2).(b).(ii) assessment of hematologic disorder severity and/or stage, as measured by physical signs and laboratory evaluation; (Core) IV.B.1.b).(2).(b).(v) indications for and application of immunophenotypic and molecular studies for patients with neoplastic and blood disorders; (Core) IV.B.1.c).(12) Fellows must demonstrate knowledge of the indications, complications, and risks and limitations associated with lesion biopsy detection of circulating DNA for disease specific markers. (Core)	IV.B.1.b).(1).(d).(vi).(a)	
IV.B.1.b).(2).(b).(v) indications for and application of immunophenotypic and molecular studies for patients with neoplastic and blood disorders; (Core) IV.B.1.c).(12) Fellows must demonstrate knowledge of the indications, complications, and risks and limitations associated with lesion biopsy detection of circulating DNA for disease specific markers. (Core)	IV.B.1.b).(1).(d).(vi).(b)	neoplasms, myelodysplasias, acute and chronic leukemias, Castleman disease, and dendritic cell
IV.B.1.c).(12) Fellows must demonstrate knowledge of the indications, complications, and risks and limitations associated with lesion biopsy detection of circulating DNA for disease specific markers. (Core)	IV.B.1.b).(2).(b).(ii)	
and risks and limitations associated with lesion biopsy detection of circulating DNA for disease specific markers. (Core)	IV.B.1.b).(2).(b).(v)	molecular studies for patients with neoplastic and blood
circulating DNA for disease specific markers. (Core)	, , ,	
1 Describe the Pavious Committee's rationals for this revision:		

- 1. Describe the Review Committee's rationale for this revision:
 - The patient care areas were updated to be consistent with and to reflect the curricular components that have been developed by the hematology subspecialty community. These components clarify the experiences required in classical hematology, malignant hematology, and medical oncology to ensure the specific skills required for education in hematology.
- How will the proposed requirement or revision improve resident/fellow education, patient safety, and/or patient care quality?
 These areas fall within the scope of the hematology specialist. Requiring fellows

to demonstrate competence in these established areas will ensure that fellows have a standard minimum knowledge and level of competence required to provide quality patient care.

- How will the proposed requirement or revision impact continuity of patient care?
 N/A
- Will the proposed requirement or revision necessitate additional institutional resources (e.g., facilities, organization of other services, addition of faculty members, financial support; volume and variety of patients), if so, how?
 N/A
- How will the proposed revision impact other accredited programs?
 N/A

Requirement #: "New" IV.C.3.b)

Requirement Revision (significant change only):

The hematology clinical experience must include an appropriate balance of inpatient and

outpatient hematology for fellows to become proficient in all curricular requirements for classical hematology. (Core)

- Describe the Review Committee's rationale for this revision:
 The proposed addition emphasizes the need to include all aspects of classical hematology in hematology fellowships.
- How will the proposed requirement or revision improve resident/fellow education, patient safety, and/or patient care quality?
 The proposed addition will ensure that fellows have a standard minimum knowledge and level of competence required to provide quality patient care.
- How will the proposed requirement or revision impact continuity of patient care?
 N/A
- Will the proposed requirement or revision necessitate additional institutional resources (e.g., facilities, organization of other services, addition of faculty members, financial support; volume and variety of patients), if so, how?
 N/A
- 5. How will the proposed revision impact other accredited programs?
 N/A